
Slide for A hand adding a box of medicine to a shelf
Our professionals provided economic evidence showing that the proposed merger would not harm competition.

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. In March 2023, Pfizer and Seagen announced that they had entered into a definitive merger agreement under which Pfizer would acquire Seagen. Counsel for Pfizer and Seagen drew upon Compass Lexecon's economic analysis and logistical support to comply with the FTC’s second request for information.
After merger reviews by competition authorities around the world, on December 14, 2023, Pfizer completed its $43 billion acquisition of Seagen — the largest M&A deal in biopharma since 2019.


Our professionals provided economic evidence showing that the proposed merger would not harm competition.

Counsel for Pfizer and Seagen drew upon Compass Lexecon's work and were able to comply with the FTC’s second request for information.
A global team of experts in the United States, Europe and Singapore provided economic analysis and logistical support throughout the regulatory review process.
In the United States, a Compass Lexecon team supported counsel through the Hart-Scott-Rodino (“HSR”) process, developing economic evidence that showed the proposed merger would not harm competition while also aiding in the process of successfully complying with the FTC’s second request for additional information.
In Europe, a Compass Lexecon team supported counsel throughout the European Commission’s Phase I investigation.
FTI Consulting es la empresa líder en el mundo en ayudar a las organizaciones a afrontar el cambio y los procesos de transformación. Liderados por profesionales con amplia experiencia, nuestros expertos responden rápidamente a situaciones dinámicas y complejas, generando un impacto que marca la diferencia.

Descubre cómo nuestro enfoque sectorial genera resultados reales en un mundo cada vez más complejo.

